accountA French biotech that has earned some global attention for its early-stage work on a hepatitis C vaccine has revealed the name of its mystery buyer. Cambridge, MA-based VBI is acquiring Epixis for an undisclosed sum, touting the potential of its work using next-gen virus-like particles in its treatments. "This acquisition enables VBI to strategically build upon our pipeline of innovative...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to VBI snares next-gen VLP tech in Epixis buyout
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account